Medical Devices

Image

Middle East and Africa Vagus Nerve Stimulation Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Nov 2022
  • MEA
  • 350 Pages
  • No of Tables: 127
  • No of Figures: 44

Middle East and Africa Vagus Nerve Stimulation Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 55.39 Million
Diagram Market Size (Forecast Year) USD 76.13 Million
Diagram CAGR %

Middle East and Africa Vagus Nerve Stimulation Market, By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymeric), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgery Centres, Specialty Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) industry trends and forecast to 2029.

Middle East and Africa Vagus Nerve Stimulation Market Analysis and Insights

The vagus nerve is a prominent component of the autonomic nervous system that regulates metabolic homeostasis and functions as a crucial component of the neuroendocrine-immune axis in maintaining homeostasis via its afferent and efferent pathways. Any approach that stimulates the vagus nerve, including manual or electrical stimulation, is referred to as Vagus Nerve Stimulation (VNS). For refractory epilepsy and treatment-resistant depression, left cervical VNS is an approved therapy.

Middle East and Africa Vagus Nerve Stimulation Market

Middle East and Africa Vagus Nerve Stimulation Market

According to the WHO, neurological diseases are responsible for 4.5% to 11% of all illnesses worldwide. Vagus nerve stimulators are also used to treat patients suffering from epilepsydepression, asthma, and cardiovascular disorders.

The Middle East and Africa vagus nerve stimulation market is expected to grow in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 4.1% in the forecast period of 2022 to 2029 and is expected to reach USD 76.13 million by 2029 from USD 55.39 million in 2021.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Year

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymeric), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgery Centres, Specialty Centers, and Others).

Countries Covered

South Africa, UAE, Egypt, Saudi Arabia, Israel, and rest of Middle East and Africa

Market Players Covered

Medtronic, LivaNova PLC, electroCore, Inc., Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, and tVNS Technologies GmbH among others.

Market Definition: Middle East and Africa Vagus Nerve Stimulation Market

The vagus nerve is a long cranial nerve that runs from a person’s brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates body functions while a person is at rest. It delivers messages to a person’s brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a person’s ears, sinuses, and esophagus as well.

VNS involves a pulse generator inserted under a person’s skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individual’s physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation.

Market Dynamics: Middle East and Africa Vagus Nerve Stimulation Market

Drivers

  • Increasing prevalence and incidence of neurological disorders

Neurological disorders cause 4.5% to 11% of all illnesses, whether in low or high-income countries. The impact is greater compared to that of malignancies, gastrointestinal diseases, or respiratory illnesses, and it is expected to grow over the next years. One of the most common neurological conditions, epilepsy, affects almost every country on earth. Most people with this illness are seen in high-population countries. Due to this rising prevalence, there is a rising demand for a variety of tools and treatments, such as VNS. More neurological problems are being treated with VNS. In addition to other clinical uses, it aids in the treatment of neurological conditions like epilepsy and depression due to the significant prevalence of neurological conditions worldwide.

  • Innovative non-invasive vagus nerve stimulation devices introduced to meet demand

Traditional and conventional VNS devices are implanted in the patient's body and leads are placed on the vagus nerves that provide electrical stimulation when required. Growing demand and technological advancement of innovative devices lead to the introduction of small-sized implantable VNS devices in the market. These small-sized implantable devices offer various clinical benefits to patients and healthcare providers. The introduction of innovative devices is anticipated to boost the market growth.

Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices

  • Rise in product approvals

The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).

For instance,

  • The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Middle East and Africa, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.

The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the Middle East and Africa region. Hence, the rise in product approvals is expected to propel market growth.

  • Product development in recent years

Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

  • Strategic initiatives by the key market players

The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.

The companies operating Middle East and Africa in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market

  • Rising government initiatives for neurological disease

The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.

Restraint/Challenge

  • High maintenance and device costs to restrain adoption of vagus nerve stimulators

The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.

Post-COVID-19 Impact on Middle East and Africa Vagus Nerve Stimulation Market

The COVID-19 outbreak had a drastic effect on Middle East and Africa healthcare with a number of countries severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Development

  • In May 2022, electroCore, Inc. announced that the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be available in 130 National Spine and Pain Centers (NSPC) affiliated locations across the U.S. for patients suffering from pain associated with different forms of primary headache. This would help the organization to develop more revenue.

Middle East and Africa Vagus Nerve Stimulation Market Scope

Middle East and Africa vagus nerve stimulation market is segmented into product type, biomaterial, application, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Implantable VNS Devices
  • External VNS Devices

Based on product type, the market is segmented into implantable VNS devices and external VNS devices.

Biomaterial

  • Ceramics
  • Metallic
  • Polymeric

Based on biomaterial, the market is segmented into ceramics, metallic, and polymeric.

Application

  • Pain Management
  • Epileptic Seizures
  • Obesity Management
  • Depression and Anxiety
  • Others

Based on application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others.

Patient Type

  • Adults
  • Pediatric
  • Geriatric

Based on patient type, the market is segmented into adults, pediatric, and geriatric.

End User

  • Hospital
  • Ambulatory Surgery Centers
  • Specialty Centers
  • Others

Based on end user, the market is segmented into hospitals, ambulatory surgery centers, specialty centers, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

Based on distribution channel, the market is segmented into direct tender, retail sales, and others.

Middle East and Africa Vagus Nerve Stimulation Market Regional Analysis/Insights 

The Middle East and Africa vagus nerve stimulation market is analyzed and market size insights and trends are provided by country, product type, biomaterial, application, patient type, end user, and distribution channel as referenced above.

South Africa dominates the Middle East and Africa vagus nerve stimulation market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting market growth.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Vagus Nerve Stimulation Market Share Analysis

The Middle East and Africa vagus nerve stimulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are Medtronic, LivaNova PLC, electroCore, Inc., Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, and tVNS Technologies GmbH among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, MEA vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.


SKU-

TABLE 1 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 37 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 38 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 52 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 53 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 SOUTH AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 SOUTH AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 SOUTH AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 60 SOUTH AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 61 SOUTH AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 62 SOUTH AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 63 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 66 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 67 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 68 UAE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 69 UAE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 UAE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 UAE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 UAE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 UAE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 UAE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 75 UAE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 76 UAE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 77 UAE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 78 UAE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 79 UAE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 80 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 81 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 82 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 83 EGYPT VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 84 EGYPT VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 EGYPT EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 EGYPT DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 EGYPT PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 88 EGYPT OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 89 EGYPT VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 90 EGYPT ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 91 EGYPT GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 92 EGYPT PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 93 EGYPT VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 EGYPT VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 96 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 97 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 98 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 99 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 100 SAUDI ARABIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 101 SAUDI ARABIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 102 SAUDI ARABIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 103 SAUDI ARABIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 104 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 105 SAUDI ARABIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 106 SAUDI ARABIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 107 SAUDI ARABIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 108 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 110 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 111 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 112 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 113 ISRAEL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 114 ISRAEL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 115 ISRAEL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 116 ISRAEL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 ISRAEL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 118 ISRAEL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 119 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 120 ISRAEL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 121 ISRAEL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 122 ISRAEL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 123 ISRAEL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 ISRAEL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 125 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 126 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 127 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials